A Study to Test the Safety of the Study Drug Fosmanogepix and How the Body Handles It in Adults With Severe Kidney Failure on Dialysis

Inclusion Criteria:

• Body mass index of 18 to 42 kg/m2, inclusive, and a total body weight > 50 kg at Screening.
• Subjects with normal renal function only: Estimated glomerular filtration rate (eGFR) ≥ 90 mL/min
• Subjects with ESRD requiring IHD only: Hemodialysis treatment for at least 3 months prior to Screening, with dialysis performed ≥ 3 times per week and adequate dialysis efficiency as established by document Kt/V ≥ 1.2 on current regimen. The clinical status of the underlying ESRD should be stable

Exclusion Criteria:

• Subjects who are pregnant, breastfeeding, or plan to become pregnant during the study.
• Laboratory abnormality or other medical or psychiatric condition, including recent (within the past year) or active suicidal ideation/behavior, that may increase the risk to study participation, or in the Investigator's judgment, make the subject inappropriate for the study.
• History or presence of clinically-significant disorders, which, in the opinion of the Investigator, are capable of significantly altering the distribution, metabolism, or elimination of the study drug.
• Renal or liver transplant recipients
• Hepatic impairment not related to ESRD
• Use of any prohibited medication within five half-lives plus 14 days prior to Day -1

Subjects with ESRD requiring IHD only:

-Not on stable dosing regimen (i.e., < 3 weeks prior to Screening) of prescription/ non prescription drugs (including dietary/herbal supplements) for the treatment of a stable concomitant disease